TapImmune to Participate in Two Upcoming Investor and Industry Conferences
March 22, 2017
Two Conferences in Two Days
[/vc_column_text][vc_empty_space height=”8px”][vc_column_text]JACKSONVILLE, FLORIDA – March 22, 2017 – TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that it will participate in two upcoming Investor and Industry conferences.
Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company’s business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY. Additionally, Dr. Wilson will serve as a panelist during the conference’s “Cancer Vaccines: Immuno-Priming and Tumor Antigens” panel discussion.
Concurrently, Dr. John Bonfiglio, President and Chief Operating Officer of TapImmune, will provide an overview of the company’s unique approach during a presentation titled “Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins,” during the S2 Oligonucleotide & Peptide Therapeutics Boston Conference in Boston, MA.
|Sachs’ 5th Annual Cancer Biopartnering & Investment Forum|
|Date:||Tuesday, March 28, 2017|
|Times:||Company presentation: 10:35 am (Eastern Time)
Cancer vaccine panel discussion: 2:00 pm (Eastern Time)
|Location:||The New York Academy of Sciences, New York, NY|
|S2 Oligonucleotide & Peptide Therapeutics Boston Conference|
|Date:||Wednesday, March 29, 2017|
|Time:||1:30 pm (Eastern Time)|
|Location:||Royal Sonesta Boston, Cambridge, MA|
The presentation of the Sachs’ 5th Annual Cancer Biopartnering & Investment Forum will be webcast live and will remain available as an archive following the presentation. To access the webcast, please visit the events page section of the TapImmune website at https://www.markertherapeutics.com/events/.